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Abstract Ischemia/reperfusion (I/R) of the heart becomes
injurious when duration of the ischemic insult exceeds a
certain threshold (approximately ≥20 min). Mitochondrial
bound hexokinase II (mtHKII) protects against I/R injury,
with the amount of mtHKII correlating with injury. Here, we
examine whether mtHKII can induce the transition from
non-injurious to injurious I/R, by detaching HKII from mi-
tochondr ia dur ing a non- in jur ious I /R in te rva l .
Additionally, we examine possible underlying mechanisms
(increased reactive oxygen species (ROS), increased oxy-
gen consumption (MVO2) and decreased cardiac energet-
ics) associated with this transition. Langendorff perfused rat
hearts were treated for 20 min with saline, TAT-only or
200 nM TAT-HKII, a peptide that translocates HKII from
mitochondria. Then, hearts were exposed to non-injurious
15-min ischemia, followed by 30-min reperfusion. I/R inju-
ry was determined by necrosis (LDH release) and cardiac
mechanical recovery. ROS were measured by DHE fluores-
cence. Changes in cardiac respiratory activity (cardiac
MVO2 and efficiency and mitochondrial oxygen tension
(mitoPO2) using protoporphyrin IX) and cardiac energetics
(ATP, PCr, ΔGATP) were determined following peptide
treatment.When exposed to 15-min ischemia, control hearts
had no necrosis and 85% recovery of function. Conversely,
TAT-HKII treatment resulted in significant LDH release and
reduced cardiac recovery (25%), indicating injurious I/R.
This was associated with increased ROS during ischemia
and reperfusion. TAT-HKII treatment reducedMVO2 and im-
proved energetics (increased PCr) before ischemia, without
affecting MVO2/RPP ratio or mitoPO2. In conclusion, a re-
duction in mtHKII turns non-injurious I/R into injurious I/R.
Loss of mtHKII was associated with increased ROS during
ischemia and reperfusion, but not with increased MVO2 or
decreased cardiac energetics before damage occurs.
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Introduction
The best method to reduce cardiac injury after ischemic heart
disease, like a myocardial infarction, is to shorten the ischemic
period by quickly restoring reperfusion. However, reperfusion
itself can paradoxically cause further injury (ischemia/
Rianne Nederlof and Ebru Gürel Gurevin contributed equally.
* Coert J. Zuurbier
c.j.zuurbier@amc.uva.nl
1 Laboratory of Experimental Intensive Care and Anesthesiology
(L.E.I.C.A.), Department of Anesthesiology, Academic Medical
Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2 Department of Biology, Faculty of Science, University of Istanbul,
34134, Fatih, Istanbul, Turkey
3 Department of Physiology, Academic Medical Center, Meibergdreef
9, 1105 AZ Amsterdam, The Netherlands
4 Cardiovascular Research Center, Mt. Sinai School of Medicine, New
York, NY 10029, USA
5 Department of Clinical and Experimental Cardiology, Academic
Medical Center, Meibergdreef 9, 1105
AZ Amsterdam, The Netherlands
6 Department of Anesthesiology, Laboratory of Experimental
Anesthesiology, Erasmus University Medical Center Rotterdam, ’s
Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
J Physiol Biochem
DOI 10.1007/s13105-017-0555-3
reperfusion (I/R) injury) and increase infarct size. This can
lead to heart failure, which is currently the highest contributor
to death caused by cardiovascular disease. If, however, the
size of the infarct is decreased, the degree of heart failure will
also decrease. Therefore, unravelling the important determi-
nants that dictate when injury starts to develop during I/R is
crucial in devising new I/R therapies.
Previous research has shown that reduced binding of the
glycolytic enzyme hexokinase II (HKII) to the mitochondria
(mtHKII) exacerbates the injury of an already injurious I/R
insult [28, 33, 39]. It is, however, unknown whether reducing
mtHKII during a normally non-injurious I/R episode can
transform it into an injurious episode. In that case, the amount
of mtHKII is an important determinant of turning reversible,
non-injurious I/R into one that is injurious. The underlying
mechanisms associated with this transition can then allude to
the important processes causing this injury. Proposed physio-
logical mechanisms linking decreased mtHKII to injury are
increased reactive oxygen species (ROS) production, in-
creased mitochondrial respiration and decreased high-energy
phosphates (phosphocreatine (PCr)) and ATP [7, 22, 25, 28].
Decreasing mtHKII was reported to increase ROS produc-
tion in isolated cardiac and brain mitochondria [7, 32], in
neonatal cardiomyocytes [39] and following an injurious I/R
period in the isolated rat heart [25]. Whether loss of mtHKII
can already induce ROS production during a much shorter
non-injurious period of ischemia in the isolated rat hearts is,
however, unknown. It has now become clear that increased
activity of the mitochondrial respiratory chain contributes to I/
R injury [3, 30]. We have shown that non-injurious ischemia,
like ischemic preconditioning (IPC), increases mtHKII [12,
41] and slows down mitochondrial activation [43], but only
with glucose present [42], suggesting a necessity for HK. In
addition, structurally obstructing HKII attachment to mito-
chondria obliterated IPC cardioprotection [1]. These findings
are commensurate with the glucose dependency of IPC [21].
From these different observations, we hypothesise that de-
creasing mtHKII may result in increased mitochondrial activ-
ity, i.e. oxygen consumption, which then can contribute to
increased I/R injury.
Finally, hexokinase binds to the voltage-dependent anion
channel (VDAC). VDAC is responsible for the transport of
adenine nucleotides and other metabolites across the outer
mitochondrial membrane (OMM) [6]. Its close proximity to
ATP/ADP exchange can give HKII an important role in car-
diac energetics (ATP and PCr). However, it is unknown
whether loss of mtHKII in the intact heart before the ischemic
period affects cardiac energetics. It is possible that decreasing
mtHKII results in impaired cardiac energetics before ische-
mia, in which impairment may then contribute to the develop-
ment of injurious I/R. Additionally, when reducing mtHKII
does indeed result in injurious I/R, cardiac energetics after
ischemia is then anticipated to be reduced as a consequence
of the increased injury (but the decreased energetics can then
not be viewed as a driver of augmented I/R injury, because the
changes occur after the I/R insult).
Therefore, in this study, we tested the hypothesis that de-
creasing mtHKII mediates the transition from non-injurious
towards injurious cardiac I/R and that this transition is associ-
ated with increased ROS production, decreased PCr and in-
creased oxygen consumption.
Methods
Animals
Animal experiments were approved by the animal Ethical
Committee of the University of Amsterdam. Male Wistar rats
(324 ± 3 g) were obtained from Charles River. Animals were
housed 2–4 per cage, fed ad libitum and were subjected to a
12-h dark/12-h light cycle.
Heart perfusion
The different perfusion protocols are presented in Fig. 1. Rats
were anaesthetised with pentobarbital (60 mg/kg), tracheoto-
my was performed and mechanical ventilation started.
Intravenous heparin (150 IU) was administered after opening
of the thorax. The aorta was cannulated in situ, perfusion
started and the heart was excised. Hearts were Langendorff
perfused at a constant flow (initial perfusion pressure
80 mmHg) at 37 °C with Krebs-Henselheit buffer (KHB)
containing the following (mM): 118 NaCl, 0.5 EDTA, 4.7
KCl, 2.25 CaCl2, 1.2 MgSO4, 25 NaHCO3, 1.2 KH2PO4
and 11 glucose gassed with 95% O2/5% CO2. End-diastolic
pressure was set at ∼3–5 mmHg using a water-filled polyeth-
ylene balloon inserted into the left ventricular cavity. Hearts
were continuously submerged in 37 °C KHB.
Peptide treatment
After a stabilisation period, hearts were treated with saline
(control group 1), 1 μM TAT-only (control group 2),
200 nM TAT-HKII or 1 μM TAT-HKII. TAT-HKII
(MIASHMIACLFTELN(β-Ala)GYGRKKRRQRRRG-am-
ide) and TAT-only (GYGRKKRRQRRRG-amide) are soluble
pept ides produced by Pepscan Presto (Lelystad,
The Netherlands). TAT-HKII translocates HKII from the mi-
tochondria to the cytosol [5, 25, 33]. Peptides were dissolved
in KHB solution and administered through a side-arm con-
nected to a mixing chamber above the heart at 1% of total
perfusion flow.
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Lactate production and NADH epifluorescence
During the execution of the present study, new research sug-
gested that high doses of TAT-HKII may induce ischemia in
the intact heart [26]. Therefore, NADH fluorescence of the
surface of the heart and effluent lactate were evaluated as
direct indices of ischemia in the 1 μM TAT-HKII group as
described before [23] and compared to the control (2.5 μM
TAT-HKII and 200 nM TAT-only) values of that study.
Ischemia/reperfusion experiments
Rat hearts were perfused as described above. Hearts were
paced at 320 bpm, and oxygen consumption (MVO2) was
measured using an oxygen sensor (World Precision
Instruments) in the left pulmonary artery. After the 20-min
stabilisation period, hearts were exposed to 20-min peptide
treatment, followed by 15-min global no-flow ischemia and
30-min reperfusion. During ischemia, hearts were submerged
in KHB gassed with 95% N2/5% CO2, and pacing was
stopped. During reperfusion, flow was slowly increased to
initial flow within the first minute of reperfusion. Venous ef-
fluent was sampled at 5-, 10-, 20- and 30-min reperfusion for
determination of lactate dehydrogenase (LDH) leakage as in-
dex of cell death.
Mitochondrial oxygen tension
Mitochondrial oxygen tension (mitoPO2) was measured in a
separate series of Langendorff perfused hearts using
protoporphyrin IX (PpIX) as described before [18, 19]. In
short, rats were injected with ALA (5-aminolevulinic acid
hydrochloride) 2 h before the heart was dissected to enhance
PpIX. Langendorff perfusion was performed as described
above, but without pacing of the heart. Hearts were exposed
for 20 min to saline or 200 nM TAT-HKII (n = 5 per group).
PpIX was excited by a laser, and its delayed fluorescence was
measured at 0-, 5-, 10-, 15- and 20-min peptide infusion.
ROS measurements
In a dedicated series of experiments for ROS measurements,
Langendorff perfused rat hearts (n = 6 per group) were ex-
posed to 20-min treatment with 1 μM TAT-only or 200 nM
TAT-HKII after which they were subjected to 15-min ischemia
followed by 30-min reperfusion. An additional small series
(n = 3) examined saline effects on ROS. Relative changes in
O2 levels were measured using DHE fluorescence as de-
scribed before [2].
Determination of mitochondrial hexokinase
Rat hearts (n = 6 per group) were Langendorff perfused and
exposed to saline, 1 μM TAT-only or 200 nM for 20 min.
Then, hearts were exposed to 15-min no-flow ischemia.
After 7-min reperfusion, hearts were homogenised as de-
scribed before [41]. The 7-min time-point was chosen, be-
cause at that time-point, the peak in ROS levels was observed.
Hearts were minced and homogenized on ice in ice-cold ho-
mogenisation medium (0.25 M sucrose, 0.02 M HEPES and
Fig. 1 Perfusion protocols used for peptide effects on ischemia
development, I/R injury and cardiac oxygen consumption,
mitochondrial PO2 within the intact heart, ROS production,
mitochondria-hexokinase binding and cardiac energetic parameters
(PCr, ATP). Hearts were perfused with saline, TAT-only or TAT-HK pep-
tide for 15–20 min after which some hearts were exposed to 15-min
ischemia and 7- or 30-min reperfusion. I/R, cardiac energetics and hearts
for hexokinase measurements were paced at 320 bpm during peptide
treatment (dotted). NADH experiments were performed during 15-min
peptide treatment. Cardiac energetics was measured at the end of peptide
treatment and at 7-min reperfusion
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1 mM dithiothreitol, pH 7.4). Part of the homogenate was
immediately centrifuged at 10,000g for 10 min at 4 °C. The
pellet, representing the mitochondrial enriched fraction, was
quickly frozen and stored at −80 °C until western blotting and
determination of HK activity. We have previously shown that
just one 10,000g centrifugation step results in a 2.5 times
mitochondrial enrichment of the pellet as compared to whole
homogenate [12]. Then, the mitochondrial enriched fraction
was dissolved in 1-mL homogenisation medium with 50-μL
10% Triton X-100 and 10-μL 100 mM glucose-6-phosphate
(to promote release of HK), stirred and incubated 15 min at
room temperature and sonificated two times for 5 s. After
centrifugation for 1 min at 10,000g, the amount of protein
was determined in the supernatant using the Bradford protein
assay.
Western blot
The amount of mtHKII was determined using western blot.
For western blot, equal amounts of protein were loaded on a
4–12% gradient gel (Biorad), electrophoresed and transferred
to a polyvinylidene membrane [24]. Membranes were incu-
bated overnight with the primary antibody against HKII
(1:1000; Cell Signalling C64G5) and the mitochondrial mark-
er COX IV (1:9000; Cell Signalling 4844). Immunoreactive
bands were visualized by the Odyssey system and quantified
using the Odyssey IRManager. All samples were analysed on
the same blot.
Lactate dehydrogenase and hexokinase activity
LDH activity in the effluent was determined as a measure of
cell death, since other studies have shown a good correlation
between LDH activity and TTC staining [20, 29]. It was de-
termined spectrophotometrically by measuring NADH oxida-
tion at 340 nm after addition of pyruvate in samples collected
5-, 10-, 20- and 30-min reperfusion at 25 °C.
HK activity was measured in mitochondrial enriched sam-
ples at 25 °C with glucose-6-phosphate dehydrogenase, glu-
cose, ATP and NAD+, in the presence of rotenone (1 μM) to
inhibit NADH breakdown by oxidoreductase enzyme activity.
Mitochondrial enriched samples were corrected for citrate
synthase (CS), a mitochondrial marker. CS was determined
at 25 °C using acetyl-CoA, oxaloacetate and di-
thionitrobenzoic acid, measuring the formation of
thionitrobenzoic acid at 412 nm.
Cardiac energetics
Cardiac energetics was measured in Langendorff perfused rat
hearts (n = 4–6 per group). Hearts were exposed for 20 min to
1 μM TAT-only or 200 nM TAT-HKII. Thereafter, for one
group, hearts were snap frozen in liquid nitrogen, weighed
and stored at −80 °C until analysis. Another group was ex-
posed to 15-min ischemia followed by 7-min reperfusion, af-
ter which the hearts were frozen.
Hearts were freeze-dried overnight and dry weight was
determined. ATP, PCr, creatinine (Cr) and inorganic phos-
phate (Pi) were determined as described by Fiolet et al. [9].
The phosphorylation potential (ΔGATP) was calculated from
these values.
Statistical analysis
Data are presented as mean + SEM. Data were analysed by an
independent t test when there were two groups, or by ANOVA
followed by a Dunnet’s post hoc test with saline as control
group when there were more than two groups. MVO2, RPP
and MVO2/RPP at baseline were analysed by a two-way
ANOVA for time and group, and Dunnet’s post hoc test when
applicable. MitoPO2 was tested using a paired t test.
Results
1 μM TAT-HKII causes ischemia
In TAT-only and 200 nM TAT-HKII-treated hearts, 15-min
peptide treatment did not lead to an increase in NADH fluo-
rescence (97 and 95% from baseline, respectively) (Fig. 2a;
published previously [23]). In addition, both treatments did
not lead to lactate production (Fig. 2b). However, 1 μM
TAT-HKII treatment caused an increase in NADH fluores-
cence to 147% of baseline (Fig. 2a). This increase was signif-
icant when compared to TAT-only (p < 0.001). In addition, it
non-significantly increased lactate production (p = 0.051)
(Fig. 2b), and perfusion pressure was significantly increased
to 112.6 mmHg after 20-min perfusion (p = 0.006) (Fig. 2c).
These results indicate that 1 μM TAT-HKII treatment causes
ischemia. Because this makes it difficult to distinguish the
effects of HKII translocation and ischemia, we decided to only
report the treatment groups (saline, TAT-only, 200 nM TAT-
HKII) for which no signs of ischemia were detected.
TAT-HKII decreases oxygen consumption but is
without effect on cardiac economy before ischemia
In both control groups, MVO2 was decreased to 96% of base-
line at the end of peptide treatment (Fig. 3a). In the 200 nM
TAT-HKII group, this decrease was significantly larger (88%
of baseline; p = 0.004). Cardiac function, as reflected by the
rate-pressure-product, only showed a non-significant trend to
decrease with TAT-HKII treatment (Fig. 3b). However, when
corrected for RPP, MVO2 was not different in the 200 nM
TAT-HKII group when compared to control groups (Fig. 3c),
indicating that cardiac economy was unaltered.
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Next to MVO2, mitoPO2 during peptide treatment was
measured in a different set of experiments. Workload in these
hearts was comparable to paced hearts (mean heart rate
277 bpm and RPP 35,384 bpm * mmHg). At baseline, there
were no differences in mitoPO2 between groups (27.3 and
25.1 mmHg for saline and 200 nM TAT-HKII, respectively).
TAT-HKII peptide treatment was not associated with a change
in mean mitoPO2 (Fig. 3d), supporting our previous results
(Fig. 2) that 200 nM TAT-HKII treatment was not associated
with cardiac ischemia.
A reduction in mtHKII turns reversible I/R injury
in irreversible I/R injury
At the end of reperfusion, both control groups showed no
signs of I/R injury. Cell death was not observed (Fig. 4a),
Fig. 3 TAT-HKII treatment decreased cardiac oxygen consumption but
was without effect on myocardial economy before ischemia. Langendorff
perfused rat hearts were exposed to 20 min saline, 1 μM TAT-only or
200 nM TAT-HKII treatment. Cardiac oxygen consumption (MVO2) (a),
cardiac function (rate pressure product (RPP)) (b) and myocardial
economy (MVO2/RPP) (c) during Langendorff perfusion.
Mitochondrial oxygen tension (mitoPO2) after 20-min peptide treatment
as percentage of baseline (d). **p < 0.01 vs saline. Mean + SEM, n = 5–8
per group
Fig. 2 Low-dose TAT-HKII caused no ischemia, whereas higher-dose
TAT-HKII caused modest ischemia. Hearts were treated for 15 min with
saline, 2.5 μM TAT-only or 200 nM or 1 μM TAT-HKII. NADH
fluorescence in the heart during the 15-min peptide treatment (a),
lactate in effluent after 15-min peptide treatment (b) and perfusion
pressure Pperf at the end of peptide treatment (c). ###p < 0.001 vs
2.5 μM TAT-only; **p < 0.01 vs saline. Mean + SEM, n = 3–4 for a
and b, n = 5–7 for c. Data for 2.5 μMTAT-only and 200 nMTAT-HKII in
a and b have been published before [23] and are provided to facilitate
direct comparisons with the 1 μM TAT-HKII peptide treatment
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RPP returned to 84 and 85% of baseline (Fig. 4b) and end-
diastolic pressure (EDP) returned to 8 and 6 mmHg (Fig. 4c)
for the saline and 1 μM TAT-only group, respectively. When
HKII was translocated from the mitochondria, extensive I/R
injury was observed: hearts had a pronounced significant rise
in LDH release (29.7 μmol/g heart weight/30-min reperfu-
sion; p < 0.001), cardiac recovery was reduced to 25% and
EDP rose to 86 mmHg (both p < 0.001). In addition, TAT-
HKII treatment decreased cardiac economy at end reperfu-
sion, as MVO2/RPP was significantly higher in TAT-HKII-
exposed group (p = 0.001) (Fig. 4d), indicating uncoupling
between oxygen consumption and force development.
TAT-HKII increases ROS
Shown in Fig. 5a are the ROS levels indexed by normalized
DHE fluorescence in TAT-control and TAT-HKII-treated
hearts before and during the I/R intervention. Also, quantified
are the ROS levels at the end of baseline, the end of ischemia
and the peak levels during early reperfusion (Fig. 5b). Before
ischemia, there were no differences in ROS levels between
groups. In contrast, TAT-HKII-treated hearts exhibited signif-
icantly greater increase in ROS levels at 15 min of ischemia
(by 63%; p = 0.039) and at the peak during reperfusion (by
96%; p = 0.04) compared to control hearts. Of note, the dif-
ference in peak ROS levels between both groups was most
pronounced during the reperfusion phase. No differences be-
tween the TAT control group and a saline group (n = 3) were
observed (data not shown).
TAT-HKII translocates HKII from mitochondria
At 7 min of reperfusion, we determined the amount of HKII in
our mitochondria-enriched fraction (Fig. 6a, b). TAT-HKII
treatment significantly reduced mtHKII binding with 26%
compared to saline (p = 0.03). Additionally, HK activity con-
firmed the results observed by western blot (Fig. 6c). HK/CS
activity, indicating both HKI and HKII activity, was reduced
13% in animals treated with 200 nM TAT-HKII (p = 0.08).
Knowing that HKI and HKII contribute approximately 50% to
cardiac HK activity [34], the 13% of total HK activity then
translates in a 26% reduction of HKII activity, commensurate
with the 26% HKII protein reduction.
TAT-HKII increased PCr before ischemia
Twenty-minute treatment with 200 nM TAT-HKII significant-
ly increased PCr when compared to TAT-only treatment (26.7
vs 21.5μmol/g dry weight, respectively; p = 0.02) (Fig. 7a). In
addition, 200 nM TAT-HKII non-significantly increased PCr/
ATP ratio, a clinical indicator for the energy state of the heart,
from 0.85 to 1.05 (p = 0.08) (Fig. 7e). No effects were
Fig. 4 A reduction in mtHKII turned reversible I/R into irreversible I/R.
Hearts were exposed to 20-min treatment with saline, 1 μM TAT-only or
200 nM TAT-HKII, followed by 15-min ischemia and 30-min
reperfusion. Total lactate dehydrogenase (LDH) activity released during
30-min reperfusion (a), rate pressure product (RPP) (b), end-diastolic
pressure (EDP) (c) and cardiac oxygen consumption (MVO2)/RPP (d)
determined at 30-min reperfusion. **p < 0.01, ***p < 0.001 vs saline.
Mean + SEM, n = 5–7 per group
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observed on ATP (Fig. 7c), inorganic phosphate (Pi), creatine
or free energy of ATP hydrolysis (ΔGATP) (data not shown).
In contrast to the effects of peptide treatment before ische-
mia, after ischemia PCr and PCr/ATP were significantly lower
with TAT-HKII treatment when compared to control (p = 0.02
and p = 0.01, respectively) (Fig. 7b, f). Also, after ischemia,
no differences in ATP were observed (Fig. 7d).
Discussion
The results of our study show that a loss of mtHKII can me-
diate the transition from non-injurious reversible I/R into one
that is injurious, suggesting that the amount of HKII bound to
mitochondria is a determinant of when I/R becomes damag-
ing. This loss of mtHKII improved cardiac energetics and
reduced oxygen consumption before I/R, negating the possi-
bility that reduced mtHKII caused increased cardiac I/R injury
due to impaired energetics or increased mitochondrial respira-
tion. In contrast, decreasing mtHKII causes increased ROS
production during the ischemia and reperfusion period, sug-
gesting the involvement of mtHKII in I/R-induced ROS pro-
duction and that increased ROS may be the trigger for injury
to start occurring.
Previous studies have shown that a reduction in mtHKII
can exacerbate I/R injury [28, 33, 39]. The amount of mtKII
has been shown to correlate with infarct size [28], and a re-
duction in mtHKII has been shown to block IPC [33], de-
crease cardiac function and alter cardiac remodelling [39]. In
addition, cardioprotective interventions, like insulin, mor-
phine and IPC, are associated with an increase in mtHKII
[41]. In this study, we observed that a reduction in mtHKII
causes cell death, increases EDP and reduces RPP after 15-
min ischemia. Factors are not affected in control hearts. The
reduction observed in RPP in control hearts can be considered
as normal deterioration over time in a Langendorff system
[42]. This is the first study showing that a reduction in
mtHKII can also turn a non-injurious episode of 15-min is-
chemia into an injurious ischemia.
Fig. 6 TAT-HKII treatment reduced mitochondrial bound hexokinase.
Hearts were treated for 20 min with saline, 1 μM TAT-only or 200 nM
TAT-HKII, exposed to 15-min ischemia and 7-min reperfusion.
Representative images of the western blots (a), semi-quantitative
amount of hexokinase II (HKII)/COX IV bound to the mitochondria as
determined by western blot (b) and HK activity corrected for citrate
synthase (CS) activity at 7-min reperfusion (c). *p < 0.05 vs saline.
Mean + SEM, n = 6 per group
Fig. 5 TAT-HKII treatment increased ROS production during ischemia
and reperfusion. ROS levels before ischemia (peptide treatment) and
during the I/R intervention (a), and ROS levels at the end of peptide
treatment, at the end of ischemia and at the peak during early
reperfusion (b). *p < 0.05 vs TAT-only. Mean + SEM, n = 6 per group
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This switch from non-injurious to injurious ischemia might
have been caused by an increase in ROS production during
ischemia and reperfusion after HKII translocation. Multiple
studies have shown that a reduction in mtHKII increases ROS
production [7, 32, 40], while an increase in mtHKII can reduce
ROS [25, 37]. ROS is an important factor in opening of the
mitochondrial permeability transition pore (MPTP) [13].
Dimerization of F0F1ATPase in the mitochondrial membrane
has recently been proposed as molecular identity of the MPTP
[11]. The MPTP opens when matrix Ca2+ and ROS levels are
high [13]. When the MPTP opens, molecules <1.5 kDa can
passage the mitochondrial membrane, finally leading to cell
death. The increase in ROS production after HKII translocation
might have caused increased MPTP opening and thereby
increased cell death. This study provides evidence that also after
a short period of ischemia, a reduction in mtHKII causes an
increase in ROS and might thereby increase cardiac cell death.
ROSmay be increased during ischemia and reperfusion after
mtHKII detachment because cytochrome c (cyt c) is released
from the intermembrane space. Previously, we showed that
cytosolic cyt c is significantly higher in reperfused hearts after
treatment with 200 nM TAT-HKII [33]. Cyt c is a powerful
superoxide scavenger present in the inner mitochondrial mem-
brane. MtHKII forms mitochondrial contact sites with other
proteins. Disruption of HKII from these contact sites might
increase permeability of the OMM, as it does in reconstituted
vesicles [1]. A translocation of HKII from the mitochondria, in
combination with increased Ca2+ levels, disrupts contact sites
Fig. 7 TAT-HKII increases PCr before ischemia, but lowers PCr after
ischemia. Hearts were treated for 20 min with 1 μMTAT-only or 200 nM
TAT-HKII. Energetics were measured at the end of peptide treatment
(baseline) or after 15-min ischemia and 7-min reperfusion.
Phosphocreatine (PCr) (a, b), ATP (c, d) and ratio PCr/ATP (e, f) at the
end of 20-min treatment (a, c, e) and after ischemia (b, d, f). *p < 0.05,
**p < 0.01 vs TAT-only at the same time-point. Mean + SEM, n = 4–6 per
group
Nederlof et al.
and increases permeability of the OMM causing cyt c to be
released [27, 33]. This will result in increased ROS.
Recently, it has become clear that respiratory inhibition is a
nodal point for several cardioprotective interventions
(nitrosylation, IPC, hypothermia, respiratory inhibitors) through
which protection against I/R injury is conferred. Previous re-
search also indirectly indicated that increasing mtHK would
slow down mitochondrial metabolism [12, 22, 42, 43]. We
therefore anticipated that reduced mtHKII would result in in-
creased oxygen consumption and thereby contribute to in-
creased I/R injury. However, our results during baseline clearly
show this not to be the case: TAT-HKII actually decreased
MVO2 in the glucose-only perfused rat heart. However, since
cardiac function also decreased, no changes in cardiac economy
were observed. Whether similar effects can be observed in
hearts perfused with different substrates will have to await fur-
ther studies. In addition, our results negate the possibility that
the transition to injurious I/R injury with TAT-HKII peptide
treatment is mediated through increased mitochondrial respira-
tion. The decreased MVO2 during baseline and the increased
economy after I/R might indicate mitochondrial uncoupling.
The results also exclude a role for impaired energetics as
mechanism provoking injurious I/R injury upon loss of
mtHKII. The increased PCr at baseline is likely a consequence
(secondary effect) of the reduction in cardiac oxygen con-
sumption: the heart’s energy turnover is decreased, resulting
in a more energetic state of the heart [8, 38]. In addition, the
lower PCr levels after ischemia are probably not caused by a
direct effect of the reduction in mtHKII, but indirectly by cell
death in these hearts.
During reperfusion, PCr in control hearts is higher than at
baseline. It is known that during reversible ischemia, PCr
levels decrease and quickly recover during reperfusion to
levels higher than before ischemia. This phenomenon is
known as ‘PCr overshoot’ [14]. The presence of PCr over-
shoot is another sign that the 15-min ischemia did not lead
to irreversible damage in control hearts [36].
Methodological considerations
In this study, we planned to use two different concentrations of
the TAT-HKII peptide. A low dose of 200 nM that was previ-
ously shown by us to decrease mtHKII without causing ische-
mia [23, 33]. The higher dose of 1 μM was chosen to study
larger effects of a loss of mtHKII. However, after start of the
experiments, Pasdois et al. suggested that the TAT-HKII peptide
impairs vascular function and that some of its effects may be
mediated by vasoconstriction of the coronary vasculature and
developing ischemia rather than dissociation of HKII from the
mitochondria [26]. We showed that the low dose of 200 nM
TAT-HKII did not cause any ischemia and that effects observed
by higher doses of the TAT-HKII peptide cannot be explained by
ischemia alone [23]. We did, however, observe that 2.5 μM
TAT-HKII increased NADH epifluorescence and increased lac-
tate production, indicating that it causesminor ischemic damage.
To exclude a role of ischemia in this study, we also measured
lactate and NADH epifluorescence after administering 1 μM
TAT-HKII, and we observed an increase in both parameters.
Because it would be difficult to separate the effects caused by
the HKII translocation and the ischemia caused by the peptide,
we decided to continue with the 200 nM TAT-HKII dose only.
The protocol used to isolate mitochondria does not lead to
isolation of a pure mitochondrial fraction, but a mitochondrial
enriched fraction. A more elaborate isolation protocol would
have led to HK dissociation from the mitochondria [16, 31].
HK in the heart is either located at the mitochondria or in the
cytosol [4, 35], and therefore, the use of a more elaborate
protocol was not necessary.
Finally, this study only looked at necrotic cell death and not
apoptosis, since its role is only significant after a longer period
of ischemia and/or reperfusion [10, 17]. In acute I/R injury,
necrosis has been observed as the main contributor to myo-
cardial cell death [15, 17].
Conclusions
The present study shows that the loss of mtHKII can be a
master switch turning reversible ischemia into irreversible is-
chemia. This loss of mtHKII is associated with increased ROS
production after ischemia, but not with increased respiratory
activity or decreased cardiac energetics at baseline.
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